A new day dawns: women without oestrogen or is a balance best?
Open Access
- 1 December 2002
- journal article
- editorial
- Published by Springer Nature in Breast Cancer Research
- Vol. 4 (6) , 1-4
- https://doi.org/10.1186/bcr538
Abstract
Building on the 30-year success story with tamoxifen, the question now is whether one agent can be used for treatment and prevention or should new medicines be targeted to specific applications? The early results with anastrozole suggest it could replace tamoxifen for treatment and should be tested as a preventive. Unfortunately, long-term testing of aromatase inhibitors will be required to avoid concerns about osteoporosis, Alzheimer's disease and coronary heart disease. Most importantly, the knowledge gained with tamoxifen has resulted in a new generation of selective oestrogen receptor modulators that can be used to prevent osteoporosis, breast cancer and uterine cancer. It is now clear that strategies utilising aromatase inhibitors and selective oestrogen receptor modulators will provide much needed options for individualised treatments.Keywords
This publication has 19 references indexed in Scilit:
- Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor InteractionsJournal of Medicinal Chemistry, 2003
- Hormone receptor status in primary breast cancer—time for a consensus?European Journal Of Cancer, 2002
- Aromatase inhibitors for the endocrine adjuvant treatment of breast cancerThe Lancet, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness AnalysisJournal of Clinical Oncology, 2002
- The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal WomenJAMA, 1999
- Designer EstrogensScientific American, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Alternative mechanisms of action of anti-oestrogensBreast Cancer Research and Treatment, 1994
- Randomized Clinical Trial of Diethylstilbestrol versus Tamoxifen in Postmenopausal Women with Advanced Breast CancerNew England Journal of Medicine, 1981